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PURPOSE: Our purpose was to compare 2 methods of treatment of chronic infection in hip arthroplasties—with or without an
antibiotic-loaded cement spacer.
METHODS: In a prospective study, we treated 68 infected hip arthroplasties with discharging sinuses and bone loss, comparing
30 patients treated in 2 stages without the use of a spacer (control group) and 38 patients treated with a vancomycin-loaded spacer
(study group). The average follow-up was 4 years (2-8.5 years). One patient died of unrelated causes 4 months after first-stage
surgery and was excluded from the study.
RESULTS: The 2-stage surgery without spacer controlled the infection in 66.7% of patients, and the 2-stage surgery using the
spacer controlled it in 89.1% (P < 0.05). At last follow-up, the average Harris Hip Score increased from 19.3 to 69.0 in the control
group versus 19.7 to 75.2 in the study group (P > 0.05). The average leg length discrepancy was 2.6 cm in the control group and
1.5 cm in the study group (P < 0.05). The patients treated with a spacer had better clinical results (81.5% of patients with good
results against 60.0% for the control group).
CONCLUSION: The use of an antibiotic-loaded spacer in the 2-stage treatment of infected hip arthroplasties provides better
infection control with good functional results and is superior to treatment in 2 stages without a spacer. Level of Evidence: Therapeutic
study, Level I-1.
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INTRODUCTION
The prevalence of deep infection following hip arthro-
plasty has been significantly reduced, although its levels
still give cause for concern.1,2
The treatment of infection is a long process often re-
quiring more than 1 surgery, causing suffering and giving
rise to extremely high financial and socials costs. Never-
theless, the prognosis for resolving infectious processes in
hip arthroplasties reaches about 80% to 90% with the cur-
rent surgical techniques.3
The control of chronic infection in arthroplasties re-
quires the removal of the prosthetic components and ex-
tensive debridement. After this, there are 3 types of proce-
dures that may be considered:4-6
1) Simple wound closure and maintenance of the patient
without an implant, through the Girdlestone surgery;7
this is a safe method as regards infectious control, but
functional outcome is poor.8,9
2) Immediate placement of a definitive prosthesis (1-stage
revision), which was widely used by European surgeons
during the 1980s and 1990s.7,10,11 Currently, this proce-
dure is contraindicated in patients infected with dis-
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charging sinuses, poor condition of soft parts, and bone
loss requiring allografts.8,12 Because a 1-stage revision
is indicated under conditions requiring the placement
of cemented components, cementless arthroplasties
should not be performed as a single-stage surgery.13
3) A 2-stage or a 3-stage surgery, which are safest and are
used worldwide.14-18
However, the traditional 2-stage procedure has several
disadvantages compared with the 1-stage surgery. During the
intermediate period, patients stay in hospital for at least 3
weeks, which is the period of skeletal traction required to
heal the soft tissues and start rehabilitation.19 Between sur-
geries, the patient has a shortened leg and is impaired re-
garding rehabilitation and function. The patient’s loss of
mobility increases the risk of pressure ulcers, osteoporosis,
and thromboembolism.20 The second stage is more difficult
than an aseptic revision due to cicatricial retraction and mus-
cular contractures that occur with leg shortening; bone land-
marks are difficult to identify during surgery.19 Disuse oste-
oporosis impairs the mechanical conditions for the fixation
of the permanent prosthesis and predisposes to fractures.21
At the beginning of the 1990s, 2 authors independently
described the use of a cement block impregnated with an-
tibiotics to fill large cavities in the acetabular and femoral
regions of patients with an infected hip arthroplasty and
severe bone loss.22,23 The spacer includes hip prosthesis
components coated with PMMA (polymethylmethacrylate)
and may be articulated as a total prosthesis24,25 or unipolar
as a partial prosthesis.26,27
Regardless of the worldwide acceptance of the spacer
as the main method of treatment of infected hip replace-
ments, no objective data have been reported in the litera-
ture to prove the real benefits of using a spacer in 2-stage
surgeries.2,28
The purpose of this study was to prospectively compare
2 methods for treating chronic infection in hip arthroplast-
ies: 2-stage surgery with and without using an antibiotic-
loaded cement spacer.
MATERIALS AND METHODS
A prospective study was performed in 68 patients di-
agnosed with chronic infected hip arthroplasties and treated
in our Institution from April 1996 to January 2003.
As inclusion criteria, all of the following were required:
1. Previous surgery with total or partial hip prosthesis;
2. Diagnosis of infection, based on bacterial identification
in cultures of samples collected during the first surgery
of the treatment;
3. Minimum time period between the arthroplasty and the
infectious condition of 4 weeks;
4. Presence of a discharging sinus communicating with the
prosthesis;
5. A written informed consent for the performance of the
study procedures, where the patient states his/her aware-
ness of the experimental character of the investigation
and the possible complications secondary to the treat-
ments.
Sixty-eight patients were randomly selected to receive
treatment in 2 stages without a spacer (control group) or
with the placement of an antibiotic-loaded cement spacer
(study group).
The mean age of patients was 54.6 years (range 16-84
years), with no difference between the groups. The male
sex prevailed, with 57.8% of the total number of patients.
Etiologies requiring most of the primary arthroplasties had
been trauma or trauma sequelae (32%), osteoarthrosis
(27%), rheumatic disease (12%), and osteonecrosis (9%).
This distribution with the high incidence of trauma patients
may be explained by the fact that our facility is a major
trauma referral center; most cases included in both groups
(60.6%) were referred from other services. The preoperative
functional evaluation of patients was performed using the
Harris Hip Score,29 and no differences were noticed be-
tween groups (average score of 16 in the control group and
18.5 in the study group, P = 0.02).
The evaluation of bone loss on the acetabular and femo-
ral side after removal of the components was made accord-
ing to the Gustilo and Pasternak classification30 (Tables 1
and 2). Most of the patients in both groups had severe femo-
ral bone loss and mild to moderate acetabular bone loss.
The bone loss was similar in both groups, with a trend of
worse femoral losses for the study group.
The spacer was similar to a Thompson’s unipolar pros-
thesis and was made in 2 phases: acetabular and femoral.28
The core of the spacer was a femoral component that was
Table 1 - Bone loss following removal of the acetabular
component, per treatment group
Grade of bone loss I II III IV
Control group 10 (33.3%) 11 (36.7%) 5 (16.7%) 4 (13.3%)
Study group 16 (42.1%) 15 (39.4%) 3 (8.0%) 4 (10.5%)
Table 2 - Bone loss following removal of the femoral
component, per treatment group
Grade of bone loss I II III IV
Control group 8 (26.7%) 6 (20.0) 3 (10.0%) 13 (43.3%)
Study group 7 (18.4%) 7 (18.4%) 5 (13.2%) 19 (50.0%)
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removed during a revision and sterilized (Figure 1); or, ide-
ally, it was a Küntscher femoral nail bent according to the
original angle between the neck and the diaphysis of the
patient’s femur (Figure 2). We used 1.0 g of vancomycin
hydrochloride powder (Vancocina CP®, Eli Lilly, Sao Paulo,
SP, Brazil ) per package of 40.0 g of acrylic cement (Sim-
plex P®, Striker Howmedica Osteonics, Rutherford, NJ,
USA ), as recommended by Penner et al31 and by Chohfi
et al.32 Typically, 2 packages of cement were used to make
the acetabular portion, and 2 to 4 packages were used to
make the femoral portion.
The patients treated without a spacer remained for 3
weeks under skeletal traction to allow fibrosis formation
at the Girdlestone resection.
Systemic antibiotics were given for 3 weeks, accord-
ing to infectious disease protocols. The empiric therapy was
1.0 g of vancomycin and 2.0 g of ceftazidime daily until
bacterial isolation. Oral antibiotics were indicated pre-
scribed until 6 months after the first surgical stage, regard-
less of whether the second stage was/was not completed.
The second stage was done only when erythrocyte sedi-
mentation speed and C-reactive protein were at normal lev-
els. In doubt, or if the increase of the values of the active
phase tests persisted, samples taken by intra-articular punc-
ture were collected for culture. If any bacterial growth was
noticed, the second surgical stage was not performed and
the treatment was considered as failed for this study18,33,34
For both stages, we report the bacteria that were iso-
lated, the surgical length of time, blood reposition, hospi-
tal stay, and complications.
Statistical Analysis
We used the chi-square test (χ2) and Fisher’s exact test
to compare the class frequencies between the groups. To
compare the magnitudes (quantitative data) between sam-
ples of the groups, the Student t test was used for samples
presenting parametric distributions, while the Mann-
Whitney U-test was used for nonparametric distributions.
To compare the magnitude of a same sample at 2 different
times (ie, pre- and posttreatment), the Wilcoxon test was
used.
RESULTS
None of the patients was lost to follow-up, which was
4 years (range, 2-8.5 years) in both groups. Three patients
died of causes unrelated to the treatment after 48 months
or more of follow-up; they were included in the study. The
final results were as follows:
Thirty patients were treated in the control group, in 2-
stages without a spacer. Of these, 1 died of septicemia af-
ter first stage and 2 died of hemorrhagic complications af-
ter the second stage. These patients account for a 10% mor-
tality related to the treatment without a spacer.
Twenty-three patients underwent reimplantation. In one
patient, this was not possible due to technical problems
during surgery.
At last follow-up, of the 20 patients with successful im-
plants, 2 reported recurrence of infection within less than
6 months after second stage and 2 had aseptic loosening
of the acetabular cup requiring revision surgery. Eighteen
Figure 2 - A – Infected THR after interthrochanteric fracture in a 74 years
old patient. Bone loss grade IV at femoral side and I at acetabular side; B –
Spacer done with a Küntscher rnail bended to simulate femoral neck angle;
C – After two years of second stage done with a wagner prosthesis and
massive femoral bone allograft the patient has no signs of infection and a
Harris hip Score of 87.
Figure 1 - Making of a spacer; A – Proximal confection of the spacer, with
bone cement (40,0g) mixed with vancomycin (1,0g) and methylen blue
covering the metal of a Müller prosthesis; B – Molding of the bone cement
in the bone acetabulum, until total drying; C – Distal confection, with the
bone cement applied to the stem; D – Stem molding, with sustained
movements to avoid fixation to the femoral canal; E – Drying of the bone
cement. Note the different blue tones, which represent the two components
done; F – Reduction of the spacer into the acetabular cavity.
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(60.0%) patients were infection-free and reported good
functional results.
Thirty-eight patients were treated in the study group
(with a spacer).
One patient died after pelvic migration of the spacer;
this was classified as a method failure.
One patient died of nontreatment-related causes (acute
cholecystitis) 4 months after the second stage and was ex-
cluded from the study.
Thirty-three patients underwent a new total joint re-
placement. Two patients had recurrent dislocations and
were treated surgically. There were 2 aseptic loosenings:
1 cementless cup was loose requiring revision after 4
months and 1 cemented stem was loose without pain after
4 years.
At the last follow-up, 31 patients (81.5%) had a good
functional prostheses with no infectious recurrences.
Bone allografts were used in 61.4% of all cases (35 of
57 second-stage surgeries), which confirms the bone loss
stated at first stage surgery
Table 3 shows that the mean duration of the first surgi-
cal stage was less in the control group (3 hours 12 min-
utes, P = 0.02), a finding that shows that the spacer in-
creased the surgical time by 40.1 minutes. At the second
stage, the mean duration of the surgery in the study group
was virtually 1 hour less (3 hours 22 minutes, P = 0.001).
Table 4 displays hospital stay which was 34.6 days for
the control group versus 24.7 days for the study group (P
< 0.001), for the 1st stage operation. Once the second stage
was performed, a significant difference was noticed in the
duration of patients’ hospitalization, with shorter hospital
stays for the study group (11.7 days against 8.2 days, P =
0.004). The interval between surgeries was equivalent in
both groups, with an average of 226.9 days (range, 70-610
days) for the control group and 162.8 days (range, 60-350
days) for the study group (P = 0.31).
Table 5 displays intensive care unit stay. No differences
were noticed between the groups in terms of number of
days during which the patients were cared for in the in-
tensive care unit after the first surgical stage, although a
trend exists towards a longer time in the hospital in the con-
trol group. The use of the spacer allowed patients to have
a shorter stay in the intensive care unit after the second sur-
gical stage (1.4 days on the average, as compared to 4.1
days for the control group, P = 0.004).) No difference oc-
curred between groups in the required amount of packed
red cell transfusion (Table 6), but less fluid drained in both
stages for the study group (Table 7).
Complications are listed in Table 8: Six spacer-related
complications occurred: 3 dislocations, 2 pelvic migrations
and 1 fracture. Of the dislocated spacers, 2 were from sur-
geries performed in the beginning of the study. We observed
that the necks of these spacers were too valgus, which fa-
cilitated lateral migration. Although these 2 spacers re-
mained dislocated, patients did not report any significant
pain condition, and it was not difficult to perform the sec-
ond surgical stage. Other complications were unrelated to
the kind of treatment, such as femoral fractures at implant
removal (9 cases), delirium (6 cases) and intestinal obsti-
pation (6 cases).
There were 4 complications related to antibiotic
therapy: 3 allergic reactions and 1 acute renal failure..
Table 3 - Duration of surgery, by treatment group (mean,
minutes)
Control Study P
First stage 192.0 232.1 0.02
Second stage 265.3 202.9 0.001
Table 4 - Length of hospital stay, by treatment group (mean,
days)
Control Study P
First stage 34.6 24.7 <0.001
Second stage 11.7 8.2 0.004
Table 5 - Length of stay in the intensive care unit, by
treatment group (mean, days)
Control Study P
First stage 2.0 1.4 0.06
Second stage 4.1 1.4 0.004
Table 6 - Number of packs of concentrated red blood cells
used after during and after surgery, by treatment group
(mean)
Control Study P
First stage 4.1 3.1 0.12
Second stage 3.9 2.6 0.16
Table 7 - Drainage after surgery, by treatment group (mean,
mL)
Control Study P
First stage 677.3 501.8 0.007
Second stage 633.3 415.8 0.01
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There was 1 case (5.0%) of recurrent dislocation in the
control group and 2 cases (6.4%) in the study group.
The incidence of intra- and postoperative complications
was not different between groups in both stages. During
the first surgical stage, we had problems while removing
the fixed femoral components, with femur fractures in 9
cases (23.7%).
Outcome is displayed in Table 9, showing a significantly
higher proportion of good results in the study group. The
mortality related to the treatment was greater in the con-
trol group (10% versus 2.6%), although without statistical
significance (P = 0.29).
On the average, the leg length discrepancy was 2.6 cm
in the control group and 1.5 cm in the study group (P = 0.02).
According to the Harris Hip Score, the final functional
outcome was better in the study group, although with no
statistical significance (P = 0.09). The average score ranged
from 19.3 to 69.0 in the control group and from 19.7 to
75.2 in the study group.
The study group had a better final outcome, with 81.5%
having good results versus 60.0% of the control group (P
< 0.001).
Recurrence of infection (Table 10). was significantly
higher for the control group, where it occurred in 7 patients
(23.3%) 7 to 112 days (average, 36.0 days) after the first
stage. These patients were treated with successive surgical
debridements, muscular flaps, or antibiotic-loaded cement
spacers. Three patients (8.1%) reported recurrence of in-
fection after the second stage accounting to an overall in-
fection failure of treatment in 33.3% of the patients.
In the study group recurrence of infection occurred in
2 patients after first stage (5.2%) and in 2 patients (6.1%)
after second stage. The overall infection rate was 10.5%
in the patients treated with a spacer.
Table 11 displays isolated bacterium species: Gram-
positive bacteria were the most frequently isolated during
the first surgical stage (68.5%), with prevalence of Staphy-
lococcus aureus (31.5%), coagulase-negative staphilococci
(13.7%), and Enterococcus faecalis (13.7%).
DISCUSSION
The use of a spacer reduced the mean duration of the
second surgical stage in 1 hour. Reimplantation without a
spacer is difficult because it is hard to find the surgical
planes, identify the bone structures, and build the bed to
accept the prosthesis. An extensive fibrosis results in ex-
tended surgery time.
On average, after the first surgical stage, the control
group patients stayed in hospital almost twice as long as
patients of the study group The use of a spacer reduced
the hospital stay, because the skeletal traction period is
mandatory to allow healing of the soft parts in patients
treated without a spacer.
Although we did not estimate the cost of treatment for
Table 8 - Incidence of complications, by treatment group
and totals
Control Study Total
Spacer dislocation* 3 3
Intrapelvic migration of spacer* 2 2
Spacer fracture* 1 1
Femoral fracture at implant removal 4 5 9
Delirium 3 3 6
Intestinal obstipation 2 4 6
Deep vein thrombosis 2 2 4
Antibiotic allergy 2 1 3
Aseptic acetabular loosening 2 1 3
Recidivant disclocation 1 2 2
Thigh abcess 2 2
Nerve damage 2 2
Acute hemorrhage leading to death 2 2
Aseptic femoral loosening 1 1
Nausea and sickness 1 1
Retroperitoneal abscess 1 1
Genital edema 1 1
Acute renal failure due to antibiotics 1 1
Headache 1 1
Anaphylaxis due to morphine 1 1
Pneumonia 1 1
Femoral diaphysial pseudarthrosis 1 1
Herpes zoster 1 1
Acute colicystitis, sepsis, and death 1 1
Acute hemorrhage and hypovolemia 1 1
Inability to implant prosthesis at second stage 1 1
* Spacer related complication
Table 9 - Outcome of the treatment, by treatment group
Control Study P
Treament related mortality 10.0% 2.6% 0.29
Final leg length discrepancy (cm) 2.6 1.5 0.02
Functional results (points 39.7 54.5 0.09
improvement in Harris Hip Score
from first consultation to last
follow-up)
Final results (% of good results 60,0% 81.5% < 0.001
at last follow-up)
Table 10 - Recurrence of infection after first and second
stages, by treatment group
Recurrence After After Overall
of infection first stage second stage
Control group 7 (23.3%) 3 (8.1%) 10 (33.3%)
Study group 2 (5,2%) 2 (6.1%) 4 (10.5%)
P 0.04 0.01 0.002
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patients in this study, the shorter hospital stay, shorter op-
erating room time, and shorter intensive care unit stay of
the study group must definitely lead to a lower cost of the
treatment with a spacer as compared to that without a
spacer.
A technical impossibility of performing permanent ar-
throplasty during the second surgical stage occurred in 1
patient of the control group, a fact also reported by
Fitzgerald35 and Charlton et al.20 This difficulty is typical
of the second surgical stage in surgeries without a spacer,
in which case it is difficult to dissect the muscular planes
and identify bone landmarks.
In the initial trial with the PROSTALAC® Duncan and
Beauchamp27 reported 3 cases of spacer dislocation among
15 patients. After 9 years in the revision of 135 cases2,8 only
2 more of such complications exist, showing that the ex-
perience acquired with the performance of the method pre-
vents dislocation from occurring. Due to a pelvic migra-
tion of a spacer and subsequent injury of the iliac vessels
and death of 1 patient, we do not place the spacer as a uni-
polar prosthesis in patients with acetabular bone weakness,
particularly in obese and rheumatoid patients (Figure 3).
In this case, we recommend the placement of a cement ball
with antibiotics that fills the acetabular cavity and that ar-
ticulates with the component implanted in the femoral re-
gion.
It is important to note that severe bleeding occurred dur-
ing the second surgical stage of the control group, with 2
deaths directly related to acute hemorrhage. The dead space
left after the removal of components is replaced by a
hematoma when a spacer is not placed. This blood collec-
tion causes continuous blood loss that is difficult to con-
trol and forms the extensive fibrotic tissue found at
reimplantation. The dissection of this fibrosis leads to ex-
cessive bleeding and to hemorrhagic complications.
Tsukayama et al36 reported 2 infection-related deaths
among 98 patients. Fisman et al37 estimate that the mor-
tality associated with infected hip prostheses is 0.4% to
1.2% for 65-year-old patients and 2.0% to 7.0% for 80-
year-old patients. During the 3 months that followed the
prosthesis removal and the surgical cleaning, mortality dou-
bled for both types of patients.
In both our groups of treatment the dislocation rate was
similar to reported data, after the treatment of infected ar-
throplasties, which is 7.3% to 12.7% of the
cases14,16,21,29,30,37,39 regardless of the method employed.
The high incidence of severe femoral loss (up to 19
cases) in the study group demonstrates the long duration
of the infectious activity in patients. Severe bone loss makes
the treatment even more difficult, since more sophisticated
reconstruction techniques are needed during the second sur-
gical stage. It is hard to make a comparison with our se-
ries due to the variety of classification systems used. Berry
and Chandler38 and English et al18 showed variable bone
loss in all cases, and Alexeef et al40 found severe femoral
bone loss in 11 cases. Rudelli41 found severe bone loss in
65% of cases treated with 1-stage surgery and bone graft-
ing.
Alexeeff et al40 used massive femoral grafts in 9 cases
without infectious recurrence after a 4-year follow-up. The
Exeter technique was adopted by English et al18 with in-
fection resolution in 92.5% of 44 cases and good functional
Table 11 - Bacteria isolated on cultures during first stage
(73 bacteria in 68 patients, 2 patients with 2 or more isolated
microorganisms)
GRAM-POSITIVE BACTERIA 50 (68.5%)
Staphylococcus aureus 23 (31.5%)
Staphylococcus epidermidis, Staphylococcus cohnii and
coagulase negative Staphylococci 10 (13.7%)
Enterococcus faecalis 10 (13.7%)
Streptococcus viridans  3 (4.1%)
Streptococcus agalactiae  2 (2.7%)
Corinebacterium sp  1 (1.4%)
Streptococcus mitis  1 (1.4%)
GRAM-NEGATIVE BACTERIA 23 (31.5%)
Escherichia coli 4 (5.5%)
Enterobacter cloacae 4 (5.5%)
Proteus mirabilis 3 (4.1%)
Serratia marcenses 3 (4.1%)
Klebsiella sp 3 (4.1%)
Acinetobacter baumannii 1 (1.4%)
Aeromonas hydrophilia 1 (1.4%)
Citrobacter diversus 1 (1.4%)
Pseudomonas aeruginosa 1 (1.4%)
Providencia sp 1 (1.4%)
Stenotrophomonas maltophilia 1 (1.4%)
Figure 3 - A – Two components spacer made in a massive bone loss in the
acetabular and femoral side of a 42 years-old female with Rheumatoid
Arthritis, after her second infected revision; B – The same case after one
year of follow-up of a second stage with reconstruction of bone loss with
allografts, acetabular cement cage and femoral cementless stem.
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results. Hanssen and Osmon42 reported 4 infectious recur-
rences in 7 patients reconstructed with structured graft of
the proximal femur. Rudelli used a homologous bone graft
in 36 one-stage treated cases, 9 of them with discharging
sinuses, and reached a 88.9% rate of infectious control with
a minimum follow-up period of 2 years in the cases with
discharging sinuses.41
In our patients, there were no mechanical complications
with the massive allografts that were used in 14 patients in
the study group and 8 patients in the control group. Main-
taining and reconstructing bone stock is fundamental for
young patients who will be subjected in the future to new
revisions and require a mechanically resistant bone structure
for the replacement of worn-out components (Figure 4).
The tendency towards better functional results in the
study group might be due to the advantage that the reha-
bilitation is performed immediately after the start of the
intermediate period. In addition to early rehabilitation in
the intermediate period, the use of the spacer led to less
surgical aggression in the second surgical stage, with im-
mediate, less painful postoperative handling and early func-
tional recovery.
In both groups the mean leg length discrepancy was ac-
ceptable when compared to those of Alexeeff et al,40 who
found no discrepancy greater than 3.0 cm when they used
a spacer and tissue bank in the second stage, and also to
the data of Charlton et al20 who, after the treatment with a
spacer achieved full correction in only 50% of the patients.
The identification of Gram-negative bacteria in 22 cases
does not contradict the validity of the use of vancomycin
added to acrylic cement. Gram-negative bacteria are not
sensitive to a single type of antibiotics, a behavior that is
adopted by Gram-positive bacteria against vancomycin. The
sensitivity spectrum of Gram-negative bacilli varies be-
tween aminoglycosides and first to fourth generation
cephalosporins and quinolones; therefore, it is difficult to
select 1 antibiotic to cover all Gram-negative bacteria. Koo
et al43 tried to solve this problem by adding vancomycin,
gentamycin, and cefotaxime to the acrylic cement. They
found infectious control in 95% of patients, but 4 cases
(20%) reported side effects due to the antibiotic, with he-
patic dysfunction and medullar depression. In our opinion,
the addition of antibiotics to the cement to cover Gram-
negative bacteria should be directed and implemented only
in case of previous identification of the agent in an appro-
priately collected culture. This concern is important from
the perspective of hospital infection control, since it pre-
vents the conditions favorable to proliferation of multire-
sistant bacteria.
Infectious control, both after the first and second sur-
gical stages, was better in the study group—this being the
main subject of this article.
After the first surgical stage, the infectious control was
poorer in the control group; this is probably due to the colo-
nization of the extended hematoma that occupied the dead
space left by the extraction of the metallic implants.
We believe that the follow-up time after second stage
is still short and that more accurate analyses should be per-
formed after 5 years of follow-up.
The overall success achieved in both groups was infe-
rior to that reported by other authors who treated infections
in 2 stages (72.0% to 97.7%) with a minimum 1-year fol-
low-up period.2,3,9,15,18,37,42,44 Our results are similar to those
reported by Hunter and Dandy,45 with 33.3% of infectious
control and by Cierny and DiPasquale46 with 64.0%, who
treated patients with severe bone loss, as in our case.
All our patients showed discharging sinuses on physi-
cal examination, which characterizes the chronicity and
severity of infections.44 According to most au-
thors,2,8,15,16,22,28,39,40,47-50 the presence of discharging sinuses
contraindicates the performance of a 1-stage treatment. On
the other hand, several studies,7,13,14,51 including the com-
munication by Rudelli et al,41 report performance of 1-stage
revisions even in the presence of discharging sinuses.
A B C
D E F
Figure 4 - A – Third revision of a THR done in a 45 years old male with
Anchilosing Spondylitis. Broken and infected Exeter stem; B – During first
stage surgery, there is methylen blue stained at the mesh and dead morselized
and impacted bone; C – After removal of the dead bone and infected implants
there is a big bone loss classified as Gustilo-Pasternak type IV; D – Spacer
introduced and just before reduction into the acetabular cavity; E – Massive
femoral allograft at second stage, fixed with cement into the stem. The stem
was fixed without cement, with distal interlocking screw and reinforcement
with bone strips; F – After three years of follow-up, there is no recurrence of
infection and good function (Harris Hip Score is 89).
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The indications for either 1-stage or 2-stage treatments
are not very clear and vary a lot from one treatment center
to the next. We agree with Elson,52 who states that a dan-
gerous situation occurs when a given author advocates a
single treatment method. There should not be any competi-
tive element in this issue, and it all will depend on the cor-
rect comparison of personal results with those found by
other investigators. The choice between 1-stage surgery and
2-stage surgery is not so important, since the experienced
surgeon knows what is achieved using the selected method.
A 2-stage approach should be used in chronically ill
patients, especially those with bone loss and with discharg-
ing sinuses. Our overall infection control with both treat-
ments was 73.1%, a value considered desirable in the lit-
erature.1-4
CONCLUSIONS
We conclude that the 2-stage treatment of infected hip
arthroplasties using antibiotic-loaded cement spacer is su-
perior to the 2-stage surgery performed without the spacer,
and that the use of the spacer provides better infectious con-
trol, as well as better functional outcomes.
RESUMO
Cabrita HB, Croci AT, Camargo OP de, Lima ALLM de.
Estudo prospectivo do tratamento das artroplastias
infectadas do quadril sem e com o uso de espaçador de
cimento com antibiótico. Clinics. 2007:62(2):99-108.
OBJETIVO: As revisões em dois tempos continuam sendo
os métodos preferidos no tratamento das artroplastias
infectadas do quadril. O procedimento em dois estágios
apresenta várias desvantagens teóricas, ainda não
comprovadas por estudos comparativos.
MATERIAIS E MÉTODOS: Em um estudo prospectivo,
tratamos 68 pacientes com artroplastias infectadas de
quadril com perdas ósseas e fístulas ativas, comparando 30
casos tratados em dois tempos sem espaçador (grupo
controle) e 38 casos tratados em dois tempos com o uso
de um espaçador de cimento adicionado a vancomicina
(grupo de estudo). Um paciente faleceu após quatro meses
da cirurgia e foi excluído do estudo. O seguimento médio
foi de quatro anos (2-8,5 anos).
RESULTADOS: A cirurgia em dois tempos sem espaçador
controlou a infecção em 66,7% dos casos comparada a
89,1% (p<0,05) nos casos tratados com espaçador. No
último seguimento, o Escore de Harris para Quadril passou
de 19,3 a 69,0 no grupo controle e de 19,7 para 75,2 no
grupo do estudo (p>0,05). A média de discrepância de
membros inferiores foi de 2,6cm no grupo controle e de
1,5cm nos grupo do estudo (p<0,05). O grupo tratado com
espaçador teve melhores resultados clínicos ao final do
estudo (81,5% de bons resultados comparados a 60,0% do
grupo tratado sem espaçador).
CONCLUSÃO: O uso de espaçador adicionado a antibióticos
no período intermediário do tratamento das artroplastias
infectadas do quadril em dois tempos proporciona melhor
controle de infecção, com bons resultados funcionais, sendo
superior à cirurgia em dois tempos sem espaçador.
UNITERMOS: Quadril. Infecção. Artroplastia. Espaçador.
Cimentos para ossos.
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